CS
RIGL icon

Credit Suisse’s Rigel Pharmaceuticals RIGL Stock Holding History

Credit Suisse’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$11 – 3635
2022
Q4 		$11 Sell
1
-12,096
-100% -$111K ﹤0.01% 3729
2022
Q3 		$143K Buy
12,097
+90
+0.7% +$1.22K ﹤0.01% 3342
2022
Q2 		$136K Sell
12,007
-1,659
-12% -$33.3K ﹤0.01% 3455
2022
Q1 		$409K Buy
13,666
+891
+7% +$24.1K ﹤0.01% 3083
2021
Q4 		$338K Buy
12,775
+377
+3% +$11.4K ﹤0.01% 4067
2021
Q3 		$450K Buy
12,398
+1,869
+18% +$73.6K ﹤0.01% 3871
2021
Q2 		$458K Sell
10,529
-5,853
-36% -$221K ﹤0.01% 3895
2021
Q1 		$561K Sell
16,382
-17,286
-51% -$685K ﹤0.01% 3697
2020
Q4 		$1.18M Sell
33,668
-4,655
-12% -$135K ﹤0.01% 3223
2020
Q3 		$919K Buy
38,323
+22,180
+137% +$545K ﹤0.01% 2994
2020
Q2 		$296K Buy
16,143
+241
+2% +$4.34K ﹤0.01% 3589
2020
Q1 		$247K Sell
15,902
-15,984
-50% -$340K ﹤0.01% 3541
2019
Q4 		$683K Buy
31,886
+1,224
+4% +$25.2K ﹤0.01% 3384
2019
Q3 		$574K Buy
30,662
+4,990
+19% +$103K ﹤0.01% 3358
2019
Q2 		$669K Buy
25,672
+8,226
+47% +$186K ﹤0.01% 3222
2019
Q1 		$448K Sell
17,446
-4,335
-20% -$99.1K ﹤0.01% 3398
2018
Q4 		$501K Buy
21,781
+5,816
+36% +$164K ﹤0.01% 3253
2018
Q3 		$513K Sell
15,965
-72,204
-82% -$2.17M ﹤0.01% 3283
2018
Q2 		$2.5M Buy
88,169
+71,914
+442% +$2.56M ﹤0.01% 2271
2018
Q1 		$575K Sell
16,255
-4,820
-23% -$193K ﹤0.01% 3293
2017
Q4 		$817K Buy
21,075
+12,272
+139% +$467K ﹤0.01% 3140
2017
Q3 		$223K Sell
8,803
-3,495
-28% -$85K ﹤0.01% 3887
2017
Q2 		$335K Sell
12,298
-12,350
-50% -$338K ﹤0.01% 3398
2017
Q1 		$816K Sell
24,648
-40,331
-62% -$1.03M ﹤0.01% 3011
2016
Q4 		$1.55M Buy
64,979
+44,609
+219% +$1.28M ﹤0.01% 2649
2016
Q3 		$748K Buy
20,370
+9,410
+86% +$270K ﹤0.01% 3184
2016
Q2 		$244K Buy
10,960
+7,308
+200% +$182K ﹤0.01% 3783
2016
Q1 		$76K Sell
3,652
-10,400
-74% -$257K ﹤0.01% 3862
2015
Q4 		$426K Buy
14,052
+8,520
+154% +$258K ﹤0.01% 3498
2015
Q3 		$136K Buy
5,532
+11
+0.2% +$328 ﹤0.01% 4050
2015
Q2 		$177K Buy
5,521
+1,761
+47% +$67.3K ﹤0.01% 4268
2015
Q1 		$134K Sell
3,760
-570
-13% -$15.6K ﹤0.01% 4172
2014
Q4 		$98K Sell
4,330
-7,919
-65% -$160K ﹤0.01% 4439
2014
Q3 		$237K Buy
12,249
+6,282
+105% +$177K ﹤0.01% 4053
2014
Q2 		$217K Sell
5,967
-6,496
-52% -$221K ﹤0.01% 4300
2014
Q1 		$484K Sell
12,463
-9,659
-44% -$344K ﹤0.01% 3733
2013
Q4 		$631K Buy
22,122
+12,247
+124% +$359K ﹤0.01% 3620
2013
Q3 		$354K Sell
9,875
-23,344
-70% -$852K ﹤0.01% 3695
2013
Q2 		$1.11M Buy
+33,219
New +$1.51M ﹤0.01% 2706

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse's RIGL Position: Q1 2023 in Review

Credit Suisse sold out of Rigel Pharmaceuticals (RIGL) in Q1 2023, closing a stake of 1 share — an estimated $11 sold.

Credit Suisse first reported a position in RIGL in Q2 2013 and held it in 39 quarters. The position peaked at $2.5M in Q2 2018. 124 funds tracked by Wall St. Rank hold RIGL as of Q1 2023.

  • Credit Suisse reported no remaining Rigel Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 1 Rigel Pharmaceuticals share in Q1 2023, an estimated $11.
  • Credit Suisse first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 39 quarters.
  • Credit Suisse's Rigel Pharmaceuticals position peaked at $2.5M in Q2 2018.
  • 124 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.